CA
NZ
UK
AU
IND
US
Johnson & Johnson reports oncology revenue climbing at high‑teen rates, targeting at least $50 billion in cancer drug sales by 2030 and projecting just over $100 billion in total revenue this year. The surge bolsters its dividend‑king profile, making the stock appealing for income …
GXO Logistics reported earnings per share of $0.50 for the quarter ending March 31, exceeding estimates of $0.37. The strong performance underscores its strategic focus on the growing healthcare sector’s logistics needs, especially in cold storage for medications like GLP-1s.[CTA: Subscribe to our healthcare …
Lisata Therapeutics (NASDAQ: LSTA) has terminated its pending merger after the buyer could not fund the $4.00 per share offer, triggering a $2,000,000 termination fee. Investors face heightened uncertainty as the company now must consider alternatives, potentially affecting share value amid a 51.5% one‑month …
Liminatus Pharma, Inc. has failed to maintain compliance with Nasdaq's minimum bid price rule, with its shares falling below $1 for 30 consecutive days. Investors should be alert as the company prepares a written response to Nasdaq by July 27, 2026, determining its continued …
Outlook Therapeutics (NASDAQ: OTLK) has received U.S. FDA approval for ONS-5010/LYTENAVA™ for the treatment of wet age-related macular degeneration, marking the first ophthalmic bevacizumab approved specifically for this condition. The approval, announced July 24, 2026, positions the company for 12 years of market exclusivity, …
NewAmsterdam Pharma has received a positive CHMP opinion for Ubeslo® and Evlarco®, paving the way for potential commercialization in Europe. This milestone highlights the company's focus on addressing significant unmet needs in cardiovascular disease therapies, promising strong market potential for investors.[CTA: Subscribe to our …
MannKind Corp has entered into a private placement agreement that will generate $50 million for the company. This funding is aimed at meeting financial obligations linked to the recent FDA approval of Furoscix ReadyFlow™, thus strengthening its operational capacity.[CTA: Join our daily market newsletter]Key …
Regeneron shareholders who bought shares between Aug 1 2025 and May 15 2026 must act before Sep 14 2026 to join a securities class action, after the company’s Phase III trial missed its primary endpoint, causing a $45.41 (6.2%) slide and a later $68.57 …
Pediatrix Medical Group (NYSE: MD) has installed David Haddock as Executive Vice President, General Counsel and Secretary, marking its 11th leadership transition since mid‑2022. The move offers investors continuity in legal and administrative oversight as the stock, up over 23% this year, navigates a …
Sartorius Stedim Biotech S.A. reported a second-quarter earnings per share of $1.77, exceeding the expected $1.22, despite a 6.9% drop in share price. Investors reacted negatively as year-to-date share performance remains down significantly.[CTA: Join our daily market newsletter]Key HighlightsSartorius Stedim Biotech reported an earnings …
Please wait processing your request...